In the case of AstraZeneca's combination, six out of 24 advanced lung cancer patients had adverse events rated as serious, or grade 3/4, and three had events that led to discontinuation of treatment. There was one treatment-related death.
AZ MEDI still killin it !!
Aucun commentaire:
Enregistrer un commentaire